Home > Insider Trading > Filing (0001209191-23-059558)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1819411	Gain Therapeutics Inc.	GANX	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1370820	Matthias Alder	C/O Gain Therapeutics, Inc. 4800 Montgomery Lane, Suite 220 Bethesda MD 20814	Chief Executive Officer	Yes	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2023-12-20	637	$0.00	5,492	No	4	M	Direct
Common Stock	Disposition	2023-12-21	206	$2.46	5,286	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Restricted Stock Units	Disposition	2023-12-20	637	$0.00	637	$0.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
7,013			No	4	M	Direct

Footnotes

Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.4602 to $2.485 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The RSUs vested 25% on September 20, 2023 and the remainder vested or shall vest in 12 equal quarterly installments thereafter, subject to Reporting Person's continuous service through each such vesting date.